Drug Trial Radar · NCT06441227
Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
Jun 13, 2024
Primary completion
Jan 9, 2025
Study completion Jan 9, 2025
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled phase I clinical study. The primary objective is to evaluate the safety, tolerability, PK, and PD of single- and multiple-dose HRS-5346 in healthy subjects, and to evaluate the food effects on PK of HRS-5346.
Conditions
- Lipoprotein Disorder Disease
Interventions
HRS-5346 tabletsDrug
Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
placeboDrug
Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the incidence and severity of adverse events in healthy subjects after single and multiple doses of HRS-5346 tabletsTime frame: About three months from the first medication to the evaluation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.